Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study

Abstract

Early diagnosis is critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools have limited sensitivity. Here we report a large-scale multicenter study involving training and validation cohorts of 3,262 participants. We show that serum levels of soluble scavenger receptor-A (sSR-A) are increased in patients with RA and correlate positively with clinical and immunological features of the disease. This discriminatory capacity of sSR-A is clinically valuable and complements the diagnosis for early stage and seronegative RA. sSR-A also has 15.97% prevalence in undifferentiated arthritis patients. Furthermore, administration of SR-A accelerates the onset of experimental arthritis in mice, whereas inhibition of SR-A ameliorates the disease pathogenesis. Together, these data identify sSR-A as a potential biomarker in diagnosis of RA, and targeting SR-A might be a therapeutic strategy.

Serum Calprotectin (S100A8/A9): A Promising Biomarker in Diagnosis and Follow-up in Different Subgroups of Juvenile Idiopathic Arthritis

“…In addition, current medical practice suggests an increasingly personalized medicine. Thereby, more and more studies, such as ours, are investigating molecules of interest that can guide the therapeutic process, often derived from promising studies in the broad eld of rheumatoid arthritis [32][33][34]] that could inspire further future studies in JIA. Furthermore, it has recently been shown that sCal can be easily and rapidly detected in blood using a lateral ow immunoassay (LFIA) based technology, which may provide a useful point-of-care testing.…”

ACPA-negative rheumatoid arthritis: From immune mechanisms to clinical translation

“…Another recent study identified increased serum levels of soluble scavenger receptor-A (sSR-A) in patients with RA which correlate with clinical and immunological features of the disease. 75 Importantly, higher sSR-A can be detected in 63% patients with early RA and 66% established RA patients, including 50% of ACPA À RA. 75 Although the pathogenic mechanisms of sSR-A in RA remains unclear, mice deficient in SR-A or administered with SR-A inhibitor displayed less disease severity, suggesting that targeting this molecule may have a therapeutic potential in RA.…”

New laboratory biomarkers of rheumatoid arthritis

“…Частота увеличения концентрации SR-A в зависимости от длительности РА составила 53,6% (<6 месяцев), 60,1% (<12 месяцев) и 63,4% (<24 месяцев). На фоне терапии отмечена связь между снижением концентрации sSR-A, коррелирующим с положительной динамикой индекса DAS28<2,6 [90].…”